Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dynavax Technologies (DVAX)

Dynavax Technologies (DVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,278,758
  • Shares Outstanding, K 117,425
  • Annual Sales, $ 277,250 K
  • Annual Income, $ 27,310 K
  • EBIT $ 10 M
  • EBITDA $ 4 M
  • 60-Month Beta 0.89
  • Price/Sales 4.64
  • Price/Cash Flow 69.21
  • Price/Book 2.41

Options Overview Details

View History
  • Implied Volatility 187.78% (-48.12%)
  • Historical Volatility 33.85%
  • IV Percentile 97%
  • IV Rank 44.50%
  • IV High 385.05% on 10/13/25
  • IV Low 29.62% on 02/26/25
  • Expected Move (DTE 12) 0.43 (3.90%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 139
  • Volume Avg (30-Day) 131
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 10,221
  • Open Int (30-Day) 10,051
  • Expected Range 10.47 to 11.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.01
  • Number of Estimates 2
  • High Estimate 0.08
  • Low Estimate -0.05
  • Prior Year 0.05
  • Growth Rate Est. (year over year) -80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.50 +3.71%
on 11/06/25
11.58 -5.96%
on 11/25/25
+0.59 (+5.73%)
since 11/05/25
3-Month
9.20 +18.37%
on 09/15/25
11.58 -5.96%
on 11/25/25
+0.83 (+8.25%)
since 09/05/25
52-Week
9.20 +18.37%
on 09/15/25
14.63 -25.56%
on 03/07/25
-1.94 (-15.12%)
since 12/05/24

Most Recent Stories

More News
Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

EMERYVILLE, Calif. , Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...

DVAX : 10.89 (-0.64%)
Dynavax Technologies: Q3 Earnings Snapshot

Dynavax Technologies: Q3 Earnings Snapshot

DVAX : 10.89 (-0.64%)
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

EMERYVILLE, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...

DVAX : 10.89 (-0.64%)
VXRT : 0.3627 (-1.97%)
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

EMERYVILLE, Calif. and SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing...

DVAX : 10.89 (-0.64%)
VXRT : 0.3627 (-1.97%)
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

EMERYVILLE, Calif. , Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines,...

DVAX : 10.89 (-0.64%)
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

EMERYVILLE, Calif. , Oct. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...

DVAX : 10.89 (-0.64%)
Dynavax Announces Management Restructuring Changes

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Dynavax (...

DVAX : 10.89 (-0.64%)
Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference

EMERYVILLE, Calif. , Aug. 27, 2025 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

DVAX : 10.89 (-0.64%)
Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile

EMERYVILLE, Calif. , Aug. 21, 2025 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...

DVAX : 10.89 (-0.64%)
Dynavax Technologies: Q2 Earnings Snapshot

Dynavax Technologies: Q2 Earnings Snapshot

DVAX : 10.89 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development...

See More

Key Turning Points

3rd Resistance Point 11.15
2nd Resistance Point 11.09
1st Resistance Point 10.99
Last Price 10.89
1st Support Level 10.83
2nd Support Level 10.77
3rd Support Level 10.67

See More

52-Week High 14.63
Fibonacci 61.8% 12.56
Fibonacci 50% 11.91
Fibonacci 38.2% 11.27
Last Price 10.89
52-Week Low 9.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar